• Product NameCHIR-98014
• Brief DescriptionInhibitors
• Purification99.41%
• Biological ActivityCHIR-98014 is a selective GSK3 inhibitor with IC50s of 0.65 nM and 0.58 nM for GSK-3α and GSK-3β; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
• Target NameFGFR inhibitor; GSK-3 inhibitor; S6 Kinase inhibitor; Src inhibitor
• CAS No. 252935-94-7
• Calculated MW 486.31
• Formulation C20H17Cl2N9O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:NC1=C(C=CC(NCCNC2=NC=C(N3C=CN=C3)C(=N2)C2=C(Cl)C=C(Cl)C=C2)=N1)[N+]([O-])=O
  Pathways:PI3K/Akt/mTOR signaling; Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors
  Receptor:bFGFR; GSK-3α; GSK-3β; p70 S6K; c-Src
  Boling pt:
  Melting pt:
  Solubility:DMSO: 8 mg/mL warmed (16.45 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Ring DB,et al. Diabetes. 2003, 52(3), 588-595.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting